Defence Announces Extension of Private Placement, Continues Development of Its Radiopharmaceuticals and ADC Programs

newsfileNov 5 07:15

Defence's Corporate Updates, Arranges Financing

newsfileSep 27 19:00

Defence Appoints New Interim Chief Executive Officer

newsfileAug 31 08:00

Defence Therapeutics Collaboration Agreement With Orano to Develop the Next Generation of Targeted Radio-Immunotherapy for Cancer Advances

newsfileAug 13 15:15

Defence Receives No Objection Letter From Health Canada for Phase I Trial of Its ACCUM-002 (AccuTOX) as an Anti-Cancer Molecule in Patients With Melanoma

newsfileJul 8 15:15

Defence's AccuTOX Boosts and Synergizes With Immune Checkpoint Inhibitors

newsfileJun 29 05:08